Ligand Pharma (LGND) Tops Q3 EPS by 3c

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.13 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand